Bromocriptine use is associated with decreased smoking rates.

Bromocriptine use is associated with decreased smoking rates.

Dopaminergic transmission in the central nervous system is thought to underlie addictive behaviours, including smoking. One effective smoking cessation drug, bupropion, enhances dopaminergic transmission; conversely, antipsychotic drugs, which are dopamine antagonists, are associated with increased...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Murphy, M, Hey, K, Johnstone, E, Munafo, M, Walton, R, Willis, B, Harrison, P
Natura:	Journal article
Lingua:	English
Pubblicazione:	2002

Documenti analoghi

Association of the mu-opioid receptor gene with smoking cessation.
di: Munafò, MR, et al.
Pubblicazione: (2007)

The genetic basis for smoking behavior: a systematic review and meta-analysis.
di: Munafò, M, et al.
Pubblicazione: (2004)

Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial.
di: Johnstone, E, et al.
Pubblicazione: (2007)

Association of COMT Val108/158Met genotype with smoking cessation.
di: Munafò, MR, et al.
Pubblicazione: (2008)

Central Hyperthermia Treated with Bromocriptine
di: P. Natteru, et al.
Pubblicazione: (2017-01-01)

Does cigarette smoking increase time to conception?
di: Munafo, M, et al.
Pubblicazione: (2002)

Zyban for smoking cessation in a general practice setting: the response to an invitation to make a quit attempt.
di: Johnstone, E, et al.
Pubblicazione: (2004)

Is giving up smoking on the nicotine patch related to genotype?
di: Yudkin, P, et al.
Pubblicazione: (2001)

Smoking cessation, weight gain, and DRD4 -521 genotype
di: Munafò, MR, et al.
Pubblicazione: (2006)

Cabergoline or bromocriptine for prolactinoma?
di: Nicolás Triantafilo, et al.
Pubblicazione: (2016-09-01)

Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial
di: Munafo, M, et al.
Pubblicazione: (2009)

Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial.
di: Munafò, MR, et al.
Pubblicazione: (2009)

Smoking status moderates the association of the dopamine D4 receptor (DRD4) gene VNTR polymorphism with selective processing of smoking-related cues.
di: Munafò, MR, et al.
Pubblicazione: (2008)

Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch.
di: David, S, et al.
Pubblicazione: (2008)

Lack of association of OPRM1 genotype and smoking cessation.
di: Munafò, MR, et al.
Pubblicazione: (2013)

Genes and cigarette smoking.
di: Munafò, MR, et al.
Pubblicazione: (2008)

No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation.
di: David, S, et al.
Pubblicazione: (2002)

Bromocriptine in the Management of Central Hyperthermia
di: Krishnaprasad Narayanankutty, et al.
Pubblicazione: (2024-08-01)

Repurposing of Bromocriptine for Cancer Therapy
di: Ean-Jeong Seo, et al.
Pubblicazione: (2018-10-01)

Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial.
di: Yudkin, P, et al.
Pubblicazione: (2004)

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
di: Rebecca Simon, et al.
Pubblicazione: (2018-10-01)

Bromocriptine and insulin sensitivity in lean and obese subjects
di: L Bahler, et al.
Pubblicazione: (2016-11-01)

DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
di: Grossman, A, et al.
Pubblicazione: (1985)

Depot-bromocriptine treatment for prolactinomas and acromegaly.
di: Grossman, A, et al.
Pubblicazione: (1986)

Bromocriptine for type 2 diabetes mellitus
di: Ooi, Cheow Peng, et al.
Pubblicazione: (2013)

Bromocriptine in type 2 diabetes mellitus
di: C Shivaprasad, et al.
Pubblicazione: (2011-01-01)

Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation.
di: Spruell, T, et al.
Pubblicazione: (2012)

Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials.
di: David, S, et al.
Pubblicazione: (2011)

Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch.
di: Yudkin, P, et al.
Pubblicazione: (2003)

CHRNA3 rs1051730 genotype and short-term smoking cessation.
di: Munafò, MR, et al.
Pubblicazione: (2011)

A peripartum cardiomyopathy case treated with bromocriptine
di: Dilek Yeşilbursa, et al.
Pubblicazione: (2021-03-01)

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
di: Ismail, I.S., et al.
Pubblicazione: (1994)

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
di: O A Gerasimenko, et al.
Pubblicazione: (2011-12-01)

Maternal smoking during late pregnancy and offspring smoking behaviour.
di: Munafò, MR, et al.
Pubblicazione: (2006)

Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement.
di: Uhl, G, et al.
Pubblicazione: (2010)

Effects of dopamine D2 receptor gene polymorphisms on smoking cessation: Abstinence and withdrawal symptoms
di: Munafo, MR, et al.
Pubblicazione: (2007)

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis
di: Yiqun Tang, et al.
Pubblicazione: (2023-03-01)

The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
di: Grossman, A, et al.
Pubblicazione: (1987)

Weekly versus basic smoking cessation support in primary care: a randomised controlled trial.
di: Aveyard, P, et al.
Pubblicazione: (2007)

The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial.
di: David, S, et al.
Pubblicazione: (2007)